Home Blog

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

0

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols

Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.

Further to the Company’s news release dated June 16, 2021 (the “Initial News Release“), Entheon closed the amalgamation agreement dated June 15, 2021 (the “Agreement“) with Lobo and 13089363 Canada Inc. (“Subco“), a wholly-owned subsidiary of Entheon, whereby Subco and Lobo amalgamated by way of a “three-cornered” amalgamation in accordance with the Canada Business Corporations Act to form one corporation, continuing under the name “Lobo Genetics Inc.”, as a wholly owned subsidiary of the Company (the “Transaction“).

The Transaction

Pursuant to the Agreement, the Company issued an aggregate of 5,000,000 common shares in the capital of the Company (the “Consideration Shares“) to the former Lobo shareholders. In addition, Entheon issued an aggregate of 9,603 incentive stock options (the “Replacement Options“) to the holders of the outstanding stock options of Lobo (the “Lobo Stock Options“) in exchange for the cancellation of the Lobo Stock Options, and all outstanding common share purchase warrants in the capital of the Lobo were cancelled. For more information about the Consideration Shares and the Replacement Options, please see the Initial News Release.

The Company also entered into an advisory agreement with John Lem, founder and former Chief Executive Officer of Lobo, to serve as a strategic advisor of industry affairs on Entheon’s advisory board. In connection with his appointment, the Company granted to Mr. Lem an aggregate of 200,000 stock options, in accordance with the terms and conditions of the Company’s stock option plan and the policies of the Canadian Securities Exchange (“CSE“). Each stock option is exercisable for one common share of the Company for a period of 5 years from the grant date at an exercise price of $0.33, based on the closing price of the Company’s shares on July 28, 2021, with 25% of the stock options vesting every 6 months from the date of grant. Mr. Lem will continue to advise and assist with the operations and strategic direction of Lobo Genetics Inc. and HaluGen Life Sciences Inc.

“We are thrilled that the transaction with Lobo has successfully completed, and we very much look forward to working with the Lobo team toward our combined mission of researching a genetic-driven approach to developing personalized psychedelic-assisted psychotherapeutic (PAP) protocols to treat substance use disorders,” said Chief Executive Officer of Entheon, Timothy Ko. “With the acquisition of Lobo comes the addition of key staff members and enhanced expertise in the field of genetics. With increased capacity to screen patients, on a genetic basis, for underlying psychiatric disorders prior to undertaking PAP, Entheon is furthering its commitment toward safety and predictability in psychedelic therapies while aggregating data that can be used to determine which psychedelic molecules are best-suited for a particular patient.”

Mr. Lem commented, “Lobo is pleased to officially join the Entheon team. We are excited to continue to leverage our technology platform to help personalize the psychedelics experience through genetic testing and data-driven insights.”

Lobo Genetics Inc.

Lobo is a Toronto-based personalized genetics company with a direct-to-consumer (DTC) platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

For more information, please contact the Company at:

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
https://entheonbiomedical.com/

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
Quast@BullseyeCorporate.com

Cautionary Note on Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, the anticipated business plans and expectations of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as “pro forma”, “plans”, “expects”, “will”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and expectations of the Company, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.

The CSE has not approved nor disapproved the contents of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91676

Red Light Holland Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

0

Toronto, Ontario–(Newsfile Corp. – July 30, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles, is pleased to announce that its financial results for the year ended March 31, 2021 (“FY21”) have been filed on SEDAR. Separately, the Company has entered into a definitive agreement as part of completing its previously announced acquisition of Mera Life Sciences (“Mera”).

Financial Statements

The Company is pleased to announce that its annual financial statements for the year ended March 31, 2021 are now available on SEDAR and highlights key data points below:

– Q4 FY21 revenue grew 535% over Q3 FY21

– During FY21, the Company realized approximately $1.3 million gain on the sale of marketable securities

– As SR Wholesale was acquired on March 19, 2021, a limited portion of SR Wholesale’s revenue could be attributed to the Company’s financial results for FY21

– Since being acquired, SR Wholesale has generated $700,000+ of revenue on an unaudited basis, a substantial portion of which is expected to be recognized on the Company’s Q2 FY22 financial results, alongside larger volumes of truffles from the second batch

– Product from the Company’s second, 1,000,000-gram harvest, was not available until after this reporting period and thus is not reflected on the Company’s FY21 results

Mera Life Sciences

The Company has also entered into a definitive agreement (the “Acquisition Agreement“), dated July 29, 2021, pursuant to which Red Light Holland will acquire 100% of the issued and outstanding shares of Mera for $2,450,000. The consideration is comprised of up to 7,000,000 common shares of the Company (the “Red Light Shares”), based on a price per Red Light Share of $0.35. The transaction is subject to several closing conditions, however the Company expects closing to take place during the first week of August, 2021. Mera is a pioneer licensee in St. Vincent and the Grenadines (“SVG”) that has spent the last 17 months working with government agencies and scientists to develop a Modern Medicinal Wellness Industry in the country.

The Red Light Shares will be released to the vendors based on the achievement of several milestones, which include: the importation of iMicrodose truffles to SVG; the approval of the transfer of the license by the government from Mera to Scarlette Lillie Sciences and Innovation; the successful prescription and sale of iMicrodose truffles to at least five patients in SVG or the successful administration of iMicrodose truffles to at least five participants in a scientific treatment study in SVG; the chemical extraction and testing of the iMicrodose truffles; the successful export of iMicrodose truffles from SVG to another jurisdiction in conformity with all national and international laws applicable to the State of St. Vincent and the Grenadines; and the final implementation of SVG’s regulatory framework for the psychedelics industry.

Mera currently holds a Medicinal Industry Development License (the “License“) issued by the SVG Bureau of Standards, which permits the research, cultivation, production, development and extraction, import and export, clinical treatment facilities, and prescribed patient access in specifically licensed clinical treatment facilities for medicinal purposes and scientific research only. The License applies to the following compounds: Turmeric, Aloe Vera, Papaya, Arrowroot, Soursop, Coconut, Ginger, Moringa, Ayahuasca, Mushroom, Iboga, Sassafras, Peyote, Psilocybin, Ibogaine, Dimethyltryptamine (DMT), Mescaline, Ketamine, 3-4 Methylenedioxy – Methamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), 5-Methoxy-N,N-Dimethyltrypotomine (5-MeO-DMT). The Company has worked closely with the Ministry of Agriculture and Industry, The Bureau of Standards, Dr. Jean Saville-Cummings, molecular biologist and Professor Leonard O’Garro, Executive Director Annette Mark at Invest SVG, and the SVG government to assist in the development of the final regulatory framework which will govern the Company’s expected activities in SVG. The Company has been informed by the government of SVG that it anticipates all these regulations for the psychedelics industry (current draft in substantially final form at the Office of the Attorney General) to be made law in the near future.

“This is another fantastic milestone for our company,” said Todd Shapiro, CEO and Director of Red Light Holland. “Over the last year, we have put extensive work into laying the foundation to be the true global leader in the push to provide immediate commercial access to psychedelic substances for those in need. Our objective is to consistently demonstrate quarter on quarter revenue growth, which we did this quarter, and which we expect to materially increase into our next quarter. We are also laser focused on achieving this growth while carefully managing our operating expenses, and the fact that our cash position remains very strong indicates our success in doing so. We’ve also made great investments which have paid off meaningfully!”

“In closing the acquisition of Mera, we’ve also executed on two other major initiatives; accessing new markets where possible and finalizing the addition of applied sciences capabilities to our business,” added Shapiro. Having spent a significant amount of time working with the major stakeholders in St. Vincent and the Grenadines over the last six months, I am confident that this acquisition will allow us to broaden our scope for research and development, production and patient access of psychedelic compounds in groundbreaking ways. We are proud of being international pioneers and our quest to expand into progressive and emerging psychedelic markets in various countries, in my opinion, has just begun.”

Change of Auditors

The Company has changed its auditor from McGovern Hurley LLP (the “Former Auditor“) to MNP LLP (the “Successor Auditor“). The Former Auditor resigned amicably effective March 1, 2021 after the Company’s formation of Red Light Oregon. The Company’s board of directors appointed the Successor Auditor, to fill the resulting vacancy, until the close of the next annual meeting of the Company’s shareholders. The change of auditor notice required under National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102“) and associated materials are filed on SEDAR under the Company’s profile. There were no reservations or modified opinions in any auditor’s reports nor any reportable events as defined in NI 51-102 in connection with the audits by the Former Auditor of the Company’s most recently completed financial year or any subsequent period.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include but are not limited to: the Company’s ability to complete the acquisition of Mera; the anticipated continued growth of the Company; the ability of the Company to explore further psychedelic products; the passing of legislation and regulations favourable to the Company by the government of St. Vincent and the Grenadines; and the ability of the Company to further develop operations in St. Vincent and the Grenadines.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to obtain shareholder approval Acquisition Agreement; the Company’s ability to continue as a going concern; the continued commercial viability and growth in popularity of functional mushrooms and/or magic truffles; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; the continued development of functional mushroom and magic truffle growth technology; the continued growth of the Company; the Company’s ability to obtain regulatory approval of its Acquisition Agreement; and the ability of the Company complete the acquisition of Mera.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the risks associated with the psychedelics industry in general such as operational risks in growing, competition, incorrect assessment of the value and potential benefits of various transactions; failure to obtain required regulatory and other approvals, in particular with respect to completing its acquisition of Mera; risk that the Company’s planned acquisition of Mera will not result in growth for the Company; risk that the government of St. Vincent and the Grenadines will not pass regulations and/or legislation which is favourable for the Company; risks associated with conducting business with St. Vincent and the Grenadines; expectations regarding future investment, growth and expansion of the operations of the businesses; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the cannabis and magic psychedelics industries, including the global regulatory landscape and enforcement related to cannabis and psychedelics, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis and psychedelics industries; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Red Light Holland disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91684

Radient Technologies Inc. Announces Letter of Intent to Acquire PBR Laboratories Inc.

0

Radient Expects Acquisition to Provide Significant Time and Cost Efficiencies in Bringing Cannabis Products to Market

Edmonton, Alberta–(Newsfile Corp. – July 29, 2021) – Radient Technologies Inc. (TSXV: RTI) (OTC Pink: RDDTF) (“Radient” or the “Company“), a commercial manufacturer of diverse, novel and high-quality cannabis extracts and packaged products, is pleased to announce that it has entered into a letter of intent with PBR Laboratories Inc. (“PBR Labs“) dated July 25, 2021 (the “LOI“) to acquire 100% of the issued and outstanding shares of PBR Labs, a leading consumer product-testing and development company (the “Acquisition“).

About PBR Labs:

Based in Alberta, Canada, PBR Labs is a leading scientific and consumer product-testing laboratory providing analytical and contract research services to public and private sector clients in the cannabis, pharmaceutical, biotechnology, food, natural health product, and agriculture industries. Established more than 50 years ago with a long history of operating as a cash-flow positive business, PBR Labs serves to facilitate drug development and fulfills the necessary steps in the commercial development of CPGs (consumer packaged goods) for its partners.

About the Potential Acquisition:

If the Acquisition is completed as contemplated in the LOI, management expects PBR Labs’ expertise and reputation to play a significant role in Radient’s business model as a commercial manufacturer of unique and high-quality cannabis CPGs. In addition, Radient anticipates PBR Labs will provide efficiencies from a quality assurance and product development & approval perspective, significantly reducing the cost and time typically required to bring consumer products to global markets. Radient projects that the Acquisition will allow the Company to immediately begin generating additional revenue streams, while also increasing its product margins.

Pursuant to the LOI, PBR Labs’ President, Dr. Ram Mehta, has agreed to enter into an executive employment agreement with Radient for a term of no less than two years. Additionally, the Company anticipates that PBR Labs will relocate its current business operations to Radient’s laboratory in Edmonton, Alberta. Following completion of the proposed Acquisition, Radient anticipates continuing to use the PBR Labs brand, and PBR Labs will continue its operations as a wholly owned subsidiary of Radient.

Management Commentary:

“The foundation of Radient was built on science and the pursuit of highly technical and novel solutions to some of the cannabis industry’s biggest challenges,” said Radient CEO Harry Kaura. “With the potential Acquisition of PBR Labs, we hope to continue that legacy, but with the ultimate goal of bringing products to the market that cannabis consumers actually want and making them more accessible and affordable. Dr. Mehta has worked for over five decades operating a highly successful laboratory, and we are confident that, following completion of the proposed Acquisition, he will be committed to helping us leverage and commercialize the treasure trove of intellectual property and analytical data Radient has accumulated, while still running a profitable lab.”

Comment from PBR Labs’ President, Dr. Ram Mehta:

“I am thrilled at the prospect of potentially joining Radient and working alongside its very forward-thinking CEO Mr. Kaura to develop truly unique and in-demand cannabis products. From the moment I first met Mr. Kaura he impressed me with his vision for Radient, as well as his deep-rooted knowledge of the industry and the products that are highly coveted by consumers but not readily available in most sales outlets. This a unique opportunity, and by working together I believe we can create truly novel and unique products that will fulfill the needs of all cannabis consumers, both medical and recreational.”

Terms of the LOI:

Pursuant to the terms of the LOI, in consideration for the Acquisition, the Company expects to issue nine million (9,000,000) Radient common shares pro rata to the current shareholders of PBR Labs (the “Vendors“) at a deemed price per share equal to C$0.12, for an aggregate deemed value of C$1,080,000.

Subsequent to the acceptance of the LOI, a due diligence period of no more than 45 business days is to take place, during which both Radient and PBR Labs are entitled to review details of the proposed Acquisition and finalize definitive documentation, including a formal share exchange agreement (the “Share Exchange Agreement“), as well as completing tax, accounting, business and legal due diligence.

The proposed Acquisition is an arm’s length transaction for purposes of the policies of the TSX Venture Exchange (“TSXV“) and remains subject to the approval of the TSXV. The Company will not be assuming any long-term debt in connection with the Acquisition. Completion of the proposed Acquisition is subject to a number of conditions including, 1) completion of due diligence and execution by the Company and the Vendors of the Share Exchange Agreement, 2) receipt by the Company of all requisite corporate and regulatory approvals, including approval of the TSXV, and other closing conditions customarily found in transactions similar to the proposed Acquisition. Although the proposed Acquisition is anticipated to close, there can be no guarantees that the proposed Acquisition will be completed as contemplated or at all. No finder’s fees are payable in connection with the proposed Acquisition. The common shares of Radient issued as consideration for the proposed Acquisition are subject to a hold period of four months following issuance.

About Radient

Radient Technologies is a commercial manufacturer of diverse, novel and high-quality cannabis extracts and packaged products, specializing in identifying existing market gaps and bringing products that fulfill these gaps to market. With scientific and industry expertise at its foundation, Radient develops specialty products that contain a highly engineered and unique range of cannabinoid and terpene profiles, while meeting the highest standards of quality and safety. Radient also operates a scientific and product-testing laboratory that offers unique solutions to the cannabis and wellness spaces. Please visit www.radientinc.com for more information.

For more information, please contact:

Harry Kaura, Director and Chief Executive Officer
ir@radientinc.com
Ph: 780 465 1318

Forward-Looking Information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding: the proposed Acquisition, including the Company’s ability to enter into the Share Exchange Agreement and an executive employment agreement with Dr. Mehta and complete the proposed Acquisition, the expected timing of completion of the proposed Acquisition, the receipt of corporate and regulatory approvals, and other matters related thereto; the proposed synergies among Radient and PBR Labs; the proposed benefits to Radient of the Acquisition; the business and operations of the Company; and the Company’s ability to execute its business plan. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; risks associated with operation in the cannabis sector in Canada and globally; and other risks inherent in the cannabis industry. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91625.

Radient Technologies Inc. Announces Notice of Default Regarding Filing of Its Annual Financial Statements

0

Edmonton, Alberta–(Newsfile Corp. – July 29, 2021) – Radient Technologies Inc. (TSXV: RTI) (OTC Pink: RDDTF) (“Radient” or the “Company”) announces today that it will be delayed in filing its audited annual financial statements (the “Statements”) for its financial year ended March 31, 2021 and the related Management’s Discussion and Analysis and Certifications by the Chief Executive Officer and Chief Financial Officer (collectively the “Required Filings”). Under National Instrument 51-102 of the Canadian Securities Administrators, the Required Filings are required to be made not later than today, July 29, 2021 (the “Deadline”). While every effort is being made to make the Required Filings as soon as possible, the Issuer will not be able to make the Required Filings by the Deadline.

The Company previously applied to the Alberta Securities Commission (the “Principal Regulator”), British Columbia Securities Commission, Ontario Securities Commission, the Manitoba Securities Commission, Saskatchewan Financial and Consumer Affairs Authority, Newfoundland and Labrador, Director of Securities, New Brunswick Financial and Consumer Services Commission, Nova Scotia Securities Commission, Prince Edward Island, Superintendent of Securities, and Autorité des marchés financiers pursuant to Part 4 of National Policy 12-203 (“NP 12-203”) for a Management Cease Trade Order (“MCTO”) as an alternative to a general cease trade order in connection with the possible late filing (the “Default”) of the Required Filings. In the event that the MCTO is granted, it will remain in effect until the Default is remedied. The issuance of a management cease trade order generally does not affect the ability of persons who have not been directors, officers or insiders of the Company to trade in their securities.

The Company has experienced unexpected delays in compiling the information required to prepare the Required Filings due to (i) employee turnover resulting in a lack of key personnel and (ii) Company resources being unexpectedly diverted for due diligence activities in connection with certain potential M&A transactions. Please see the Company’s press release dated June 30, 2021 for more details of the potential transactions, which is available on the Company’s SEDAR profile at www.sedar.com.

As a result of the delay in compiling such information, the Company’s auditor retained to audit the Statements has advised the Company that it will be unable to complete its audit prior to the Deadline, notwithstanding the audit is substantially complete. Consequently, the Company requires additional time to collect the requisite information and for the auditor to complete the audit. The Company anticipates that it will be able to collect the requisite information, the auditor will be able to complete the audit and the Company will be able to complete the Required Filings by August 30, 2021.

The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the filing requirements described above.

The Company has not taken any steps towards any insolvency proceeding and the Company confirms that there is no material information relating to its affairs that has not been generally disclosed.

In the last few weeks, progress has been made in collecting the requisite information to prepare the Required Filings and to complete the audit as soon as possible, and during this time the Company has been in discussions with its auditor for that purpose.

The MCTO prohibits trading in securities of the Company, whether direct or indirect, by:

(a) the Company’s Chief Executive Officer;

(b) the Company’s Chief Financial Officer; and

(c) the members of the board of directors of the Company or other persons or companies who had, or may have had, access directly or indirectly to any material fact or material change with respect to the Company that has not been generally disclosed.

Should the Company fail to make its Required Filings on or before August 30, 2021, the Principal Regulator can impose a cease trade order that all trading in securities of the Company cease for such period of time as the Principal Regulator may deem appropriate.

About Radient

Radient Technologies Inc. is a commercial manufacturer of diverse, novel and high-quality cannabis extracts and packaged products. Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Radient also has a science lab that is focused on innovation with expertise in formulations and technologies offering unique solutions in the cannabis and wellness space. Please visit www.radientinc.com for more information.

For more information, please contact:

Harry Kaura, CEO & Director
ir@radientinc.com
Ph: 780 465 1318

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the potential Default, including the Company’s ability to make the Required Filings prior to August 30, 2021. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; risks associated with operation in the cannabis sector; and other risks inherent in the cannabis industry. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91634

GreenGro Technologies Announces Exclusive Sales and Marketing Agreement with Hydroponics Retail Store

0

Anaheim, California–(Newsfile Corp. – July 29, 2021) – GreenGro Technologies, Inc. (OTC: GRNH), an established provider of eco-friendly green technologies for the industrial hemp and cannabis industries, today announced that it entered into an exclusive sales and marketing agreement with Stop N Grow, Inc., a hydroponics store that specializes in indoor and outdoor greenhouses and horticultural products. A soft grand opening for the first Stop N Grow retail store that will carry the Company’s products is expected next month in Holbrook, Arizona.

Under the terms of the exclusive agreement, Stop N Grow will market and distribute the Company’s products and services with a focus on its proprietary greenhouses, modular rooms and vertical sliding racks. It is also agreed that certain GreenGro-branded products from its hemp and cannabis operations will also be distributed through this sales channel.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2021/07/greengro-technologies-announces-exclusive-sales-and-marketing-agreement-with-hydroponics-retail-store.jpg?w=696&ssl=1

GreenGro’s Vertical Systems

To view an enhanced version of this graphic, please visit:
https://grassnews.net/wp-content/uploads/2021/07/greengro-technologies-announces-exclusive-sales-and-marketing-agreement-with-hydroponics-retail-store.jpg

“This exclusive agreement with Stop N Grow will provide us with an entirely new and scalable revenue channel as demand for our turnkey product offerings are expected to continue nationwide,” said James Haas, Chairman and COO of GreenGro Technologies, Inc. “We believe revenues from this agreement will begin positively impacting our financial performance by the third quarter of this year with expectations of a healthy growth rate from thereon.”

To be added to GreenGro’ s email list please click this link or for additional information, please call 323-380-4500.

About GreenGro Technologies, Inc.

GreenGro Technologies, Inc. (OTC: GRNH) is a vertically integrated provider of eco-friendly state-of-the-art technological solutions to the green industries. The Company is a trusted partner to the cultivation, extraction, production and retail aspects of the green market through a combination of three operating divisions: CBD Ventures, Cannabis Ventures and GenoBreeding. Each division is able to leverage the strengths of the other, creating a synergistic, efficient and highly profitable business model.

For additional information about GreenGro Technologies and its solutions, please visit 

https://www.facebook.com/GreengroTechnologiesInc or the Company’s website at www.greengrotech.com.

(Safe Harbor Act: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.)

# # #

Company Contact:
Darrel Courtney
Chief Executive Officer
Phone: 888-217-6058

Public Relations Contact:
GreenGro Public Relations
Phone: 323-380-4500

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91551

TransCanna Appoints Chief Operating Officer

0

Vancouver, British Columbia–(Newsfile Corp. – July 29, 2021) – TransCanna (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has promoted Alan Applonie from the role of General Manager to Chief Operating Officer.

“Alan has proven himself to be an incredible asset to our Company. His application of his leadership experience in industrial agriculture and consumer packaged goods has already made a huge impact on our company,” said Bob Blink, TransCanna CEO. “Perhaps most significantly, Alan has been able to help us create an efficient, organized, and success-oriented workplace culture, and he has won the respect of employees across all departments.”

Mr. Applonie has over 25 years of start-up management experience leading multiple companies from infancy to growth of over $100M USD. His deep areas of expertise include world-class team building, project management, data analytics, scaling businesses, and establishing operational efficiencies. He has held leadership positions with multinationals such as Kraft Foods, Trident Seafoods, and Taylor Farms.

He first joined TransCanna in June 2019 as General Manager in the midst of the Company’s purchase of its 196,000 square foot Daly facility, and during the acquisition of its major subsidiary Lyfted Farms. During his two-year tenure as General Manager, he successfully increased production at an existing facility by 150%, oversaw Phase 1 construction at the new facility, migrated operations from cash payments to real banking, and implemented HR management systems, employee training systems, workplace compliance safety measures, and KPI’s for every department, as well as weekly financial reporting systems.

“It’s been rewarding and worthwhile work getting the infrastructure in place in order to massively scale operations for TransCanna,” said Mr. Applonie, “Now with all the pieces in place, and an unprecedented amount of plants in process, we can see the clear path towards significant profitability in the very near future. The best is yet to come.”

In his new role as Chief Operating Officer, Mr. Applonie will lead and execute on TransCanna’s organizational strategy as it scales its cultivation production capacity and launches into new verticals such as 3rd party processing, manufacturing, distribution and crop management services. Most crucially, he will be implementing the necessary enterprise management ecosystems required to support TransCanna as it embarks its mission to be the largest vertically integrated cannabis conglomerate in California.

About TransCanna

TransCanna Holdings Inc. is a California-based, Canadian-listed company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

TransCanna’s wholly owned subsidiary Lyfted Farms is California’s authentic cannabis brand whose pioneering spirit has been continuously providing the finest cannabis flower genetics and cultivation methods since 1984. The Lyfted Farms brand of exclusive cannabis flower is sold at premium retailers throughout the state. With its new cultivation facility in Daly, California, the company is now poised to become one of the largest and most efficient vertically integrated cannabis companies in the California market.

For updated information with respect to our company, please see our filings on SEDAR at www.sedar.com and on the CSE at www.thecse.com, or visit the Company’s website at www.transcanna.com. To contact the Company, please email info@transcanna.com.

On behalf of the Board of Directors
Bob Blink, CEO

Corporate Communications:
info@transcanna.com
604-200-8853

FORWARD LOOKING INFORMATION:

Certain information in this release may contain forward-looking statements, such as statements regarding future expansions and cost savings and plans regarding production increases and financings. This information is based on current expectations and assumptions, including assumptions concerning the completion of the expansion of the Daly Facility, government approval of pro-cannabis policies, greater access to financial services and increased cultivation capacity, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include unexpected increases in operating costs, a continued strain on farmers due to fires and the Coronavirus pandemic and competition from other retailers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this release are made as of the date of this release and are included for the purpose of providing information about management’s current expectations and plans relating to the future. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

Neither the Canadian Securities Exchange (“CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91513

Quinsam Declares 27th Consecutive Dividend

0

Toronto, Ontario–(Newsfile Corp. – July 29, 2021) – Quinsam Capital Corporation (CSE: QCA) (“Quinsam” or the “Company”) wishes to announce the declaration of its regular quarterly dividend.

Dividend

The Board of Directors of Quinsam has approved the Company’s 27th consecutive quarterly dividend. The dividend is $0.00125 per share ($0.005 per share per year). The distribution will be paid on August 27, 2021 to shareholders of record on August 9, 2021. This dividend will be designated as an “eligible dividend” for Canadian income tax purposes. Future quarterly dividends will be subject to Board approval.

At the recent share price of $0.185, the current dividend yield is approximately 2.7%.

About Quinsam Capital Corporation

Quinsam is a merchant bank with a focus on “small cap” investments which it believes are undervalued. We do not invest on behalf of third parties or offer investment advice.

Generally, Quinsam does not believe that individual investments are material events. Quinsam may choose to announce certain investments once the company has finished buying its position because we feel that this information helps investors understand our decision making process. Generally, Quinsam does not announce the sale of investments.

For further information contact:

Roger Dent, CEO
(647) 993-5475
roger@quinsamcapital.com

This press release may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events, which are inherently uncertain. Forward-looking statements can often, but not always, be identified by forward-looking words such as “anticipate”, “believe”, “continue”, “expect”, “goal”, “plan”, “intend”, “estimate”, “may”, “project”, “predict”, “potential”, “target”, and “will” or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance.

By their nature, forward-looking statements require making assumptions which include, among other things, that (i) Quinsam will have sufficient capital to effect its business strategies, (ii) the business strategies will produce the results intended by Quinsam, and (iii) the markets will react and perform in a manner consistent with the business strategies.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated. Quinsam believes that the expectations reflected in the forward-looking information are reasonable but no assurance can be given that these expectations will prove to be correct. Some risks and other factors that could cause actual results to differ materially from those expressed in forward-looking information in this press release include, but are not limited to: cannabis companies Quinsam has invested in obtaining and maintaining regulatory approvals including acquiring and renewing U.S. state, local or other licenses, and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization; market and general economic conditions of the cannabis sector or otherwise, interest rates, regulatory and statutory developments, the nature of the Company’s investments, the available opportunities and competition for investments, the concentration of our investments in certain industries and sectors, reliance on key personnel, risks affecting investments, management of the growth of the Company, and exchange rate fluctuations. Readers are cautioned that the foregoing list of risks and factors is not exhaustive. Although Quinsam has attempted to identify factors that could cause actual events or results to differ materially from those described in forward-looking information, there may be factors that cause events or results to differ from those intended, anticipated or estimated.

The forward-looking information contained herein is provided as at this date, based upon the opinions and estimates of management and information available to management as at this date. Quinsam does not undertake and specifically disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information contained herein.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91470

VIVO Cannabis(TM) Subsidiary, Beacon Medical Germany GmbH, Receives First Permit to Import Medical Cannabis from Canada into Germany

0

Toronto, Ontario–(Newsfile Corp. – July 29, 2021) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company“), a leading provider of premium cannabis products and services and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc. (“ABcann”), today announced that its EU-GMP/GDP licensed subsidiary Beacon Medical Germany GmbH, has received its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), allowing the import of Canadian grown dried flower medical cannabis from VIVO’s ABcann Medicinal affiliate’s GMP-certified Napanee, Ontario site, into Europe.

“We are making great strides towards our first commercialization of product in Europe,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer. “As a leader in medical cannabis in Canada and Australia, we are delighted by the opportunity to bring our Beacon Medical™ products to market and support the increasing demand from Germany’s more than 130,000 medical cannabis clients.”

Germany import permits are issued by BfArM on a shipment-specific basis. Following the receipt of an export permit from Health Canada, the Company expects its first shipment of product to Germany, to be sold under the Beacon Medical brand, in late Q3/early Q4.

About VIVO Cannabis™

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds cultivation, processing and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s client-centric, scalable network of medical cannabis clinics, has serviced over 150,000 client visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.

For further information:
VIVO Investor Relations
+1 416-848-9839
ir@vivocannabis.com

Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company’s most recent management’s discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91552

Aleafia Health Announces the Appointment of Mark J. Sandler as Board Chair

0

TORONTO, July 29, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) a global leader in cannabis wellness products and services, is pleased to announce the appointment of Mark J. Sandler as Chairman of its Board of Directors (the “Board”). He is the longest serving member of the Company’s board, which is composed entirely of independent directors, and chairs its Governance Committee.

Currently senior partner at Cooper, Sandler, Shime, & Bergman LLP, Mr. Sandler is a leading appellate and trial lawyer, as well as an adjudicator and mediator in regulatory matters, including securities litigation. He served three terms as an elected member of the Law Society of Ontario’s governing body.

“Aleafia Health is well positioned to continue on its growth trajectory of the last three years, from a pre-revenue startup to a leading global cannabis company,” said Mr. Sandler. “In supporting the objectives of the company, we will continue to prioritize strong corporate governance, and sustainable growth in the adult-use, medical and international markets.”

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

DTx Producer Entheo Digital Will Present at the July Psychedelic Capital Event, Hosted by Microdose

0

Austin, Texas–(Newsfile Corp. – July 28, 2021) – On Thursday, July 29th, newly founded Digital Therapeutics company will be giving a presentation at Microdose’s Psychedelic Capital Event. Presenting will be the two founding executives Robin Arnott (CEO) and Lyle Maxson (CSO).

“Psychedelic Therapy is the most important movement in mental health right now, and it’s coming at a truly critical moment. These medicines are necessary to support massive psychological healing,” says Robin Arnott, CEO of Entheo Digital. “We’ve been developing SoundSelf as a tool for psychedelic work for years. Now that the world is opening up to psychedelic therapy, we’re ready to support the therapists on the front lines to prepare their clients for deep healing.”

Arnott and Maxson will be sharing insights into the powerful role that digital experiences, or “technodelics,” can play in psychedelic healing.

To watch their session, tune in to Psychedelic Capital on Thursday, July 29th at 1pm Pacific. You can use the code “ENTHEODIGITAL” for a free ticket.

For more information, or to arrange an interview, please contact:

info@entheo.digital

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91489